A Phase 3 interventional study of Nivolumab and Nivolumab + Relatlimab Fixed Dose Combination in Melanoma, sponsored by Bristol-Myers Squibb. Terminated at 184 sites in 25 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 63 under way, 9 of them phase 3. Nivolumab · Melanoma.
Among the 142 studies testing nivolumab in Melanoma, this one is the 3rd largest by enrollment, is one of 10 that started in 2021, is one of 19 in phase 3, and was the 97th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Melanoma and Skin Cancer Trials Limited · Sites in Australia
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is given beside the treatment under test here, not tested itself. Read study by study →
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 94 · Phase 3 20 · Phase 4 4
First in 2006; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,093 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 50 across the 142 interventional studies. Of the 62 that completed or were terminated, 35 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 142 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
111 studies in Melanoma by Bristol-Myers Squibb: 3 open now, 9 under way, 3 of them phase 3. Of 90 finished, 41 (46%) have results posted.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 5th largest by enrollment of the 75 interventional ones that give a count, is one of 6 that started in 2021, is one of 21 in phase 3, and was the 99th registered.
Bristol-Myers Squibb’s Melanoma studies by the year they started, since 2002.
13 of the studies testing nivolumab in Melanoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04309409Phase 3University Hospital, EssenAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | 2027-09 |
| NCT06712927Stanford UniversityTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | 2026-11 |
| NCT07155317Emory UniversityTime-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | 2026-12-31 |
| NCT03685890Vastra Gotaland RegionEvaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion | 2026-12-31 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 142 studies testing nivolumab in Melanoma, from their registry updates:
Among Bristol-Myers Squibb’s 111 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination
Biological: Nivolumab + Relatlimab Fixed Dose Combination
Monotherapy
Biological: Nivolumab
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Drug pages: Nivolumab · Relatlimab
Specified dose on specified days
Also known as: BMS-986213, Opdualag
Recurrence Free Survival (RFS)
RFS is defined as the time between the date of randomization and the first date of documented recurrence (local, regional, distant, new primary melanoma) or death due to any cause, whichever occurs first.
Time frame: Approximately 27.5 Months
Overall Survival (OS)
OS is defined as the time between the date of randomization and the date of death due to any cause.
Time frame: Approximately 27.5 Months
Distant Metastasis Free Survival (DMFS)
DMFS is defined as the time between the date of randomization and the date of first distant metastasis or date of death due to any cause, whichever occurs first.
Time frame: Approximately 27.5 Months
Progression Free Survival on Next-Line Systemic Therapy (PFS2)
PFS2 defined as time from randomization to second recurrence/objective disease progression on next-line systemic therapy per investigator, or death from any cause, whichever occurs first.
Time frame: Approximately 27.5 Months
Number of Participants With Safety Related Events
Safety related events encompass the following measures: Adverse events (AEs), Serious AEs, AEs leading to discontinuation, Drug-Related AEs and Deaths. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. An SAE is an AE which: * Results in death * Is life threatening * Requires hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event
Time frame: Approximately 27.5 Months
Number of Participants With Select AEs
Select AEs will be reported as AEs per organ class. Organ classes which will be reported: * Gastrointestinal * Hepatic * Pulmonary * Renal * Skin * Hypersensitivity/Infusion reaction
Time frame: Approximately 27.5 Months
Number of Participants With Endocrine Related Immune Mediated AEs
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity.
Time frame: Approximately 27.5 Months
Number of Participants With Non-endocrine Related Immune Mediated AEs
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity.
Time frame: Approximately 27.5 Months
Laboratory Abnormalities for Specific Thyroid Tests
Number of participants with laboratory abnormalities in specific thyroid tests.
Time frame: Approximately 27.5 Months
| Milestone | Treatment 1 | Treatment 2 |
|---|---|---|
| Started | 547 | 546 |
| Completed | 543 | 545 |
| Not completed | 4 | 1 |
| Withdrew: Withdrew consent | 3 | 0 |
| Withdrew: No longer meets study criteria | 0 | 1 |
| Withdrew: Ae unrelated to study drug | 1 | 0 |
| Milestone | Treatment 1 | Treatment 2 |
|---|---|---|
| Started | 543 | 545 |
| Completed | 283 | 327 |
| Not completed | 260 | 218 |
| Withdrew: Requested to discontinue | 26 | 5 |
| Withdrew: Withdrew consent | 7 | 1 |
| Withdrew: Study drug toxicity | 114 | 64 |
| Withdrew: Ae unrelated to study drug | 6 | 12 |
| Withdrew: Disease recurrence | 102 | 128 |
| Withdrew: Other reasons | 4 | 7 |
| Withdrew: Death | 1 | 1 |
| Milestone | Treatment 1 | Treatment 2 |
|---|---|---|
| Started | 543 | 545 |
| Completed | 1 | 5 |
| Not completed | 542 | 540 |
| Withdrew: Death | 78 | 69 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Withdrew consent | 17 | 16 |
| Withdrew: Other reasons | 444 | 452 |
RFS is defined as the time between the date of randomization and the first date of documented recurrence (local, regional, distant, new primary melanoma) or death due to any cause, whichever occurs first.
| Months | Treatment 1 | Treatment 2 |
|---|---|---|
| Recurrence Free Survival (RFS) | NA (0 to 37.7) | 33.84 (0 to 37.7) |
OS is defined as the time between the date of randomization and the date of death due to any cause.
| Months | Treatment 1 | Treatment 2 |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
DMFS is defined as the time between the date of randomization and the date of first distant metastasis or date of death due to any cause, whichever occurs first.
| Months | Treatment 1 | Treatment 2 |
|---|---|---|
| Distant Metastasis Free Survival (DMFS) | NA (NA to NA) | NA (33.84 to NA) |
PFS2 defined as time from randomization to second recurrence/objective disease progression on next-line systemic therapy per investigator, or death from any cause, whichever occurs first.
| Months | Treatment 1 | Treatment 2 |
|---|---|---|
| Progression Free Survival on Next-Line Systemic Therapy (PFS2) | NA (NA to NA) | NA (NA to NA) |
Safety related events encompass the following measures: Adverse events (AEs), Serious AEs, AEs leading to discontinuation, Drug-Related AEs and Deaths. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. An SAE is an AE which: * Results in death * Is life threatening * Requires hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event
| Participants | Treatment 1 | Treatment 2 |
|---|---|---|
| AEs | 522 | 520 |
| Drug-Related AEs | 483 | 438 |
| Serious AEs | 132 | 78 |
| AEs leading to discontinuation | 102 | 65 |
| Deaths | 83 | 76 |
Select AEs will be reported as AEs per organ class. Organ classes which will be reported: * Gastrointestinal * Hepatic * Pulmonary * Renal * Skin * Hypersensitivity/Infusion reaction
| Participants | Treatment 1 | Treatment 2 |
|---|---|---|
| Gastrointestinal | 115 | 120 |
| Hepatic | 108 | 86 |
| Pulmonary | 11 | 13 |
| Renal | 33 | 21 |
| Skin | 244 | 240 |
| Hypersensitivity/Infusion Reaction | 37 | 26 |
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity.
| Participants | Treatment 1 | Treatment 2 |
|---|---|---|
| Adrenal Insufficiency | 33 | 9 |
| Hypothyroidism/Thyroiditis | 158 | 93 |
| Hypothyroidism | 152 | 82 |
| Thyroiditis | 18 | 14 |
| Diabetes Melitus | 11 | 8 |
| Hyperthyroidism | 96 | 56 |
| Hypophysitis | 51 | 13 |
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity.
| Participants | Treatment 1 | Treatment 2 |
|---|---|---|
| Pneumonitis | 8 | 10 |
| Diarrhea/colitis | 28 | 21 |
| Hepatitis | 26 | 17 |
| Nephritis and Renal Dysfunction | 3 | 3 |
| Rash | 49 | 40 |
| Hypersensitivity | 12 | 2 |
Number of participants with laboratory abnormalities in specific thyroid tests.
| Participants | Treatment 1 | Treatment 2 |
|---|---|---|
| TSH > ULN | 229 | 159 |
| TSH > ULN WITH TSH ≤ ULN AT BASELINE | 193 | 124 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 148 | 74 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES ≥ LLN | 168 | 124 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 52 | 28 |
| TSH < LLN | 198 | 131 |
| TSH <LLN WITH TSH ≥ LLN AT BASELINE | 180 | 123 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 119 | 72 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES ≤ ULN | 117 | 85 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 27 | 19 |
Collected over Adverse Events, Serious Adverse Events and All-Cause mortality: Approximately 27.5 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment 1 | 86/547 (15.7%) | 174/543 (32%) | 489/543 (90.1%) |
| Treatment 2 | 76/546 (13.9%) | 121/545 (22.2%) | 473/545 (86.8%) |
| Event | Treatment 1 | Treatment 2 |
|---|---|---|
| HypophysitisEndocrine disorders | 13/543 | 2/545 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/543 | 12/545 |
| MyositisMusculoskeletal and connective tissue disorders | 9/543 | 0/545 |
| MyocarditisCardiac disorders | 8/543 | 1/545 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 6/543 | 0/545 |
| ColitisGastrointestinal disorders | 5/543 | 1/545 |
| DiarrhoeaGastrointestinal disorders | 5/543 | 3/545 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/543 | 5/545 |
| Adrenal insufficiencyEndocrine disorders | 4/543 | 1/545 |
| Immune-mediated enterocolitisGastrointestinal disorders | 4/543 | 3/545 |
| Event | Treatment 1 | Treatment 2 |
|---|---|---|
| FatigueGeneral disorders | 161/543 | 161/545 |
| HypothyroidismEndocrine disorders | 150/543 | 85/545 |
| DiarrhoeaGastrointestinal disorders | 114/543 | 117/545 |
| PruritusSkin and subcutaneous tissue disorders | 112/543 | 116/545 |
| COVID-19Infections and infestations | 78/543 | 110/545 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 100/543 | 110/545 |
| RashSkin and subcutaneous tissue disorders | 99/543 | 86/545 |
| HyperthyroidismEndocrine disorders | 96/543 | 60/545 |
| HeadacheNervous system disorders | 74/543 | 94/545 |
| NauseaGastrointestinal disorders | 86/543 | 54/545 |
All Randomized Participants
| Age, Continuous(Years) | Treatment 1 | Treatment 2 | Total |
|---|---|---|---|
| Mean | 57.3 ± 14.16 | 57.6 ± 13.34 | 57.4 ± 13.75 |
| Sex: Female, Male(Participants) | Treatment 1 | Treatment 2 | Total |
|---|---|---|---|
| Female | 220 | 231 | 451 |
| Male | 327 | 315 | 642 |
| Ethnicity (NIH/OMB)(Participants) | Treatment 1 | Treatment 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 46 | 39 | 85 |
| Not Hispanic or Latino | 280 | 269 | 549 |
| Unknown or Not Reported | 221 | 238 | 459 |
| Race (NIH/OMB)(Participants) | Treatment 1 | Treatment 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 39 | 37 | 76 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 491 | 497 | 988 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 14 | 10 | 24 |
Showing the first 100 of 184 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2021 to primary completion in Dec 2024, 37 months.
Results were first posted in Jan 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Relatlimab